Navigation Links
Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Date:5/17/2011

ex (NIH-CPSI) scale, which measures symptoms and impact on quality of life (-12.1 +/- 9.3 vs. -8.5 +/- 7.2; P=0.0224).  Statistically significant treatment effects were seen with RAPAFLO(R) 4 mg on the NIH-CPSI scale evaluating urinary symptoms (–2.2 +/- 2.7 vs –1.3 +/- 3.0; P=.0102). Decreases in NIH-CPSI scores with RAPAFLO(R) 8 mg did not provide any additional therapeutic benefit compared to the 4 mg dose.  

In addition, patients treated with RAPAFLO(R) 4 mg showed significantly better results relative to placebo on the physical component of another widely accepted evaluation tool, the 12-Item Short Form Health Survey (SF-12) developed to study patients with chronic conditions (4.2 +/- 8.1 vs 1.7 +/- 9.0; P=.049). In a global response assessment (GRA), 56 percent of patients treated with RAPAFLO(R) 4 mg versus 29 percent of patients receiving placebo reported moderate or marked improvement (P= 0.0069). An increase in dose to 8 mg resulted in no incremental increased effect.

Safety Findings

Overall, one in three (33.1%) of men in the study experienced a treatment-related adverse event (AE).  The incidences of drug-related AEs were similar for RAPAFLO(R) 4 mg and placebo, and included: dizziness (1.9%, 4 mg; 8.9%, 8 mg; 7.4%, placebo);  headache (0, 4 mg; 4.4%, 8 mg; 1.9%, placebo); nasal congestion (3.8%, 4 mg; 6.7%, 8 mg; 0, placebo); and decreased libido (1.9%, 4 mg; 2.2%, 8 mg; 1.9%, placebo).  The most common adverse event was retrograde ejaculation.  More men treated with RAPAFLO(R) versus placebo experienced retrograde ejaculation (26.9%, 4 mg; 40%, 8 mg; 1.9%, placebo).  Retrograde ejaculation, or an orgasm with reduced semen, is an expected and reversible effect of selective alpha blockers and thought to be a direct reflection of the product's selective binding properties.  Discontinuation rates due to a drug-related adverse event were 5.8 percent f
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Watson Confirms Renvela® Patent Challenge
2. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
3. Watsons GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
4. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
5. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
6. Vanda Pharmaceuticals Reports First Quarter 2011 Results
7. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
8. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
11. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
(Date:1/15/2014)... TX (PRWEB) January 15, 2014 More ... disease, and about 1 in 3 seniors will die ... source ). These jaw-dropping figures have shocked many Americans ... and, hopefully, help prevent these tragic age-related cognitive disorders. ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... BNVI ) will present findings on the mechanism ... BN108 at the American Association of,Cancer Research (AACR) being ... CA, April 12 - 16, 2008., Bionovo,s poster ... death) induced by BN107 and BN108. As explained by ...
... Announces Change to Unaudited Financial Results Released March 18, ... ... Bulletin Board: NGNM) announced today that it had filed with the,Securities and Exchange ... A copy of this annual report can be found at, http://www.SEC.gov ., ...
... researchers at ... with internal solutions, REDWOOD CITY, Calif., April 15 ... life science researchers, and,Pfizer Pharmaceuticals, Inc. (NYSE: PFE ... a strategic,partnership today. This new multi-year partnership promotes enterprise-wide,deployment ...
Cached Biology Technology:Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research 2NeoGenomics Files Annual Report on Form 10-KSB with the SEC 2Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis 2Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis 3
(Date:7/9/2014)... be able to cope with the rising salinity of Arctic ... today is best known for its tundra and polar bear ... 38 million years ago during what is known as the ... temperate forest with brackish water, home to a variety of ... giant tortoises. Much of what is known about the region ...
(Date:7/9/2014)... pain and fever but often can be defeated with antibiotics ... hard to beat. Now, scientists have built a new weapon ... Published in the journal ACS Applied Materials & Interfaces ... kill more of them than medicine alone. , David Leong, ... lie in wait, undetectable in the human body or in ...
(Date:7/9/2014)... sparrow-sized fossil from China challenges the commonly held belief ... the ability to fly. The birdlike fossil is actually ... the remains of a tiny tree-climbing animal that could ... Museum in Blanding, Utah, and Alan Feduccia of the ... Journal of Ornithology . , The fossil of ...
Breaking Biology News(10 mins):Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3Researchers declassify dinosaurs as being the great-great-grandparents of birds 2
... , WALL, N.J., Dec. 3 ... in wireless public safety and finger-based biometric identification solutions, ... Special Shareholder Meeting held today approved the sale of ... Inc. Of the shares voted, 98.6% were cast in ...
... Preliminary Press Conference Topics Last Call! Press ... Attention PIOs: Sending Press Releases to Fall meeting ... News Media registration information News Media Registration ... coming For important information regarding visas ...
... Have you ever felt overly upset by a social ... Scientists have long known that opium-like painkillers, called opioids, ... emotional stress. Now, a new study reviewed by Faculty of ... in the gene for the opioid receptor can determine the ...
Cached Biology News:BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6
Request Info...
... from E. coli is a ... also contains both 5'--3'and 3'--5' ... activity enables the enzyme to ... the DNA as starting points ...
Request Info...
... E. coli containing a clone of the human ... Topoisomerase II alters the topological state of nucleic ... a transient break which generates a separate DNA ... double-stranded DNA passage mechanism, the enzyme can relax ...
Biology Products: